Clinical Trials

The CTC conducts investigator-initiated collaborative clinical trials research across a diverse therapeutic areas, including cancer, cardiovascular disease, neonatal health and diabetes.

We have participated in over 100 investigator-initiated, cooperative-group clinical trials, and coordinated some of the largest randomised trials initiated by Australian investigators (LIPID and FIELD studies, each with over 9000 patients). Over 65 000 patients have been randomised to these trials.

The resources of multiple collaborative clinical groups have been consolidated through the CTC, ensuring a critical mass in specialised areas of expertise. This has helped our clinical trials program to grow in breadth and depth, particularly in oncology.

All trials undertaken through the CTC are conducted strictly according to guidelines for clinical trials research and conduct, and are audited by regulatory authorities, sponsors and the CTC itself.

Our capacity to conduct high-quality trials continues to grow through expansion in our infrastructure and strengthening and streamlining of operational processes.

Contact: Dr Wendy Hague, Clinical Trial Program Director

Current PhD opportunity-epidemiology

Post-hoc analysis in clinical trials

Background: Randomised trials provide best evidence of treatment effects, owing to their unbiased allocation of treatments to each patient group, but post hoc analysis of these trials can still lead to substantial bias of estimates of treatment effect. The extent to which this occurs is not fully appreciated by the reader. Using access to large databases of clinical trials (LIPID, FIELD, cancer trials) we will be able to produce simulated trial results (for a null treatment and a positive treatment) using intention-to-treat prespecified analyses and then compare these results with post hoc analyses, in which patient exclusions, adjusted analyses, choice of statistical test, subgroups and other post hoc choices are examined. The research will examine strategies for adjusting prespecified analyses that are free from bias and provide a clear framework to guide future trial analyses.

The suitable candidate will have a background in science or medicine, including postgraduate training in epidemiology and/or biostatistics. Demonstrated quantitative research skills and an ability to publish high-quality research are required.

To submit an expression of interest, please send 1. a cover letter, 2. curriculum vitae, and 3. academic transcripts as a single PDF to Professor John Simes by Monday, 29 August 2016.